Saad Z. Usmani, MD, FACP, Levine Cancer Institute

Articles by Saad Z. Usmani, MD, FACP, Levine Cancer Institute

Third and Subsequent Line Options for Multiple Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Updates in Relapsed/Refractory Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Updates in Multiple Myeloma in the Frontline Setting

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Rapid Readouts: Update of CARTITUDE-1

BySaad Z. Usmani, MD, FACP, Levine Cancer Institute

June 23rd 2020

Latest Updated Articles

Updates in Multiple Myeloma in the Frontline Setting
January 29th 2021
$Updates in Relapsed/Refractory Myeloma$
Updates in Relapsed/Refractory Myeloma
January 29th 2021
Third and Subsequent Line Options for Multiple Myeloma
January 29th 2021
Rapid Readouts: Update of CARTITUDE-1
June 23rd 2020

Trending on OncLive

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis